Third Harmonic Bio (THRD)

• Market cap: $465M
• 1 day: -4.44%
• 5 days: -8.91%
• 1 month: -17.04%
• 3 months: -26.23%
• 6 months: -20.74%
• Year to date: -8.19%
• 1 year: -8.02%
• 5 years: -47.56%
• 10 years: -47.56%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.

Employees: 51

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

114% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 7

79% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 19

14% more capital invested

Capital invested by funds: $525M [Q2] → $597M (+$71.7M) [Q3]

10% more funds holding

Funds holding: 77 [Q2] → 85 (+8) [Q3]

8.53% more ownership

Funds ownership: 98.59% [Q2] → 107.12% (+8.53%) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]